Emmaus Life Sciences, Inc. (EMMA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 23 | 21 | 18 | 30 | 17 | 12 | 16 | - |
| Operating profit | $m | 0 | 5 | ||||||
| Net profit | $m | 1 | -16 | -11 | -4 | -6 | -7 | -6 | - |
| EPS reported | $ | -0.12 | -0.10 | ||||||
| Operating cashflow per share | $ | -0.00 | -0.01 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.00 | -0.01 | ||||||
| Free cash flow | $m | -0 | 4 | ||||||
| Net debt | $m | 29 | 26 | ||||||
| Book value equity | $m | -64 | -66 | ||||||
| Book value per share | $ | -0.99 | -0.55 | ||||||
| Number of shares | m | 64.04 | 120.54 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.01 | -0.01 | ||||||
| P/S LTM | x | 0.07 | 0.05 | ||||||
| P/FCF LTM | x | -69.38 | 0.21 | ||||||
| EV/EBITDA LTM | x | -100.85 | 9.20 | ||||||
| EV/Sales LTM | x | 2.51 | 2.64 | ||||||
| Earnings Yield LTM | % | -9.00% | -10.31% | ||||||
| FCF Yield | % | -1.44% | +476.27% | ||||||
| Quality | |||||||||
| ROE | % | +11.78% | +13.78% | ||||||
| ROIC | % | -1.23% | -1.67% | ||||||
| Operating margin | % | +1.85% | +3.22% | ||||||
| Gross margin | % | +93.12% | +93.35% | ||||||
| FCF/Sales | % | -0.10% | -5.28% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -25.22% | -6.74% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.00 | 0.13 | ||||||
| Net Debt/EBITDA | x | -98.17 | -71.00 | ||||||
| EBIT/Net interest | x | 0.03 | 0.05 | ||||||
| Net debt/market cap | % | +37.00% | +37.18% | ||||||
| Net debt/Equity | x | -0.45 | -0.39 | ||||||
| Gross debt/equity | x | -0.51 | -0.46 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free